IRWD (Ironwood Pharmaceuticals) Beginning Cash Position: $220.5 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IRWD Ironwood Pharmaceuticals Inc IRWD
65 GF Score
Price $4.19
GF Value $4.55
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Ironwood Pharmaceuticals Beginning Cash Position?

Ironwood Pharmaceuticals IRWD -4.23% 65 Beginning Cash Position is $220.5 Mil as of Jun. 2026. GuruFocus rates IRWD with a GF Score™ of 65/100 and a GF Value™ of $4.55 (Fairly Valued). The stock has 6 warning signs investors should review.

Ironwood Pharmaceuticals's Beginning Cash Position for the quarter that ended in Jun. 2026 was $220.5 Mil.

Ironwood Pharmaceuticals's quarterly Beginning Cash Position increased from Dec. 2025 ($140.4 Mil) to Mar. 2026 ($215.5 Mil) and increased from Mar. 2026 ($215.5 Mil) to Jun. 2026 ($220.5 Mil).

Ironwood Pharmaceuticals's annual Beginning Cash Position declined from Dec. 2023 ($657.9 Mil) to Dec. 2024 ($92.2 Mil) and declined from Dec. 2024 ($92.2 Mil) to Dec. 2025 ($88.6 Mil).

Ironwood Pharmaceuticals Beginning Cash Position Related Terms

Ironwood Pharmaceuticals Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Ironwood Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ironwood Pharmaceuticals Beginning Cash Position Chart

Ironwood Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 364.78 621.86 657.94 92.15 88.56

Ironwood Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.48 92.85 140.41 215.46 220.47
IRWD
65GF Score
Ironwood Pharmaceuticals Inc IRWD
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ironwood Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $220.5 Mil mean?
Ironwood Pharmaceuticals (IRWD) has a Beginning Cash Position of $220.5 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Ironwood Pharmaceuticals and its competitors.
Is Ironwood Pharmaceuticals' Beginning Cash Position too high?
Ironwood Pharmaceuticals' current Beginning Cash Position is $220.5 Mil. Overall, Ironwood Pharmaceuticals has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ironwood Pharmaceuticals' Beginning Cash Position compare to TLRY and AQST?
Ironwood Pharmaceuticals' Beginning Cash Position of $220.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Ironwood Pharmaceuticals and its competitors. Ironwood Pharmaceuticals's current Beginning Cash Position is $220.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ironwood Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ironwood Pharmaceuticals (IRWD) is currently considered Fairly Valued. The stock's GF Value™ is $4.55, compared to a current price of $4.19 — trading 8% below its estimated fair value. The current Beginning Cash Position is $220.5 Mil. Ironwood Pharmaceuticals' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Ironwood Pharmaceuticals (IRWD), the current Beginning Cash Position is $220.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ironwood Pharmaceuticals (IRWD) Overvalued in 2026?

Based on GuruFocus' analysis, Ironwood Pharmaceuticals stock appears to be undervalued. The current stock price of $4.19 is trading 8% below its estimated GF Value™ of $4.55. GuruFocus considers Ironwood Pharmaceuticals to be Fairly Valued.

Key valuation signals for IRWD:

  • Beginning Cash Position: $220.5 Mil
  • GF Value™: $4.55 vs. price of $4.19 (8% below fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the IRWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ironwood Pharmaceuticals Business Description

Other Exchanges I76:Germany
Address 100 Summer Street, Suite 2300, Boston, MA, USA, 02110
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
65GF Score

Get the complete analysis for IRWD

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.19
Price
$4.55
GF Value